HHS Orders H1N1 Vaccines and Vaccine Antigen - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

HHS Orders H1N1 Vaccines and Vaccine Antigen

ePT--the Electronic Newsletter of Pharmaceutical Technology

The United States Department of Health and Human Services (HHS) this week placed an initial order with Sanofi Pasteur (Lyon, France) for a vaccine to fight influenza A (H1N1) infection. Valued at $190 million, the order is pursuant to an existing contract between the agency and the company and provides for the production of the bulk vaccine. However, Sanofi Pasteur still awaits the seed virus from the US Centers for Disease Control. Once the seed virus is obtained, the company says it will have a better timeline of when the vaccine might be available. Typically, it takes approximately six months to develop and manufacture an influenza vaccine. Also to be determined are the dosage requirements and the final formulation, filling, and distribution of the vaccine. Sanofi Pasteur says it “is prepared to commence commercial-scale production in June following certification of the working seed by the US Food and Drug Administration.”

The vaccine order follows an initial order by HHS of GSK’s influenza A (H1N1) antigen as the company’s proprietary AS03 adjuvant system, which the company already used in Phase II trials of an adjuvanted influenza A H5N1 (avian flu) vaccine. According to a May 15 release, GSK is also waiting on a seed virus from the World Health Organization. The company says it has also received orders from the governments of France, Finland, Belgium, and the United Kingdom for an influenza A (H1N1) adjuvanted vaccine.

See PharmTech's previous coverage:

WHO, GSK Provide Update on Pandemic Flu Production

Swine Flu Update

Q&A: How to Make a Swine Flu Vaccine

Continued Steps toward H1N1 Vaccine

Vaccines Progress Along the Critical Path



blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here